Full-Time

Senior Manager

Blockchain Developer

Deadline 8/13/25
Merck

Merck

10,001+ employees

Develops medicines and vaccines for health

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid work arrangement.

Category
💻Software Engineering (1)
Required Skills
Kubernetes
Microsoft Azure
Node.js
SQL
Docker
Blockchain
AWS
Go
Requirements
  • 3+ years of experience in blockchain administration, with a focus on Hyperledger Fabric
  • Proven experience in deploying and managing distributed ledger technologies
  • Strong understanding of Hyperledger Fabric architecture and components
  • Proficiency in programming languages such as Go, NodeJs, SQL
  • Familiarity with containerization technologies (e.g., Docker, Kubernetes)
  • Experience with cloud platforms (e.g., AWS, Azure) is a plus
Responsibilities
  • Set up and configure Hyperledger Fabric networks, including peers, orderers, and channels
  • Monitor network performance, troubleshoot issues, and ensure high availability and reliability of the blockchain infrastructure
  • Assist in the development, deployment, and management of smart contracts (chaincode) and the SDK on the Hyperledger Fabric network
  • Implement and maintain security protocols, including identity management, access control, and data privacy measures
  • Create and maintain comprehensive documentation for network architecture, configurations, and operational procedures
  • Work closely with developers, business analysts, and other stakeholders to understand requirements and provide blockchain solutions
  • Plan and execute upgrades and patches to the Hyperledger Fabric network to ensure it remains up-to-date and secure
  • Provide training and support to team members and stakeholders on blockchain technologies and best practices
Desired Qualifications
  • Certifications in blockchain technologies or cloud computing
  • Experience with other blockchain frameworks like Ethereum

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, distinguishing itself from competitors by its comprehensive support for both patients and healthcare providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Verona Pharma opens new revenue streams in respiratory diseases.
  • Investment in North Carolina vaccine site expands production capabilities, boosting market share.
  • Focus on HIV treatment development addresses global health challenges, enhancing market opportunities.

What critics are saying

  • Increased competition in cardio-pulmonary market may lead to pricing pressures.
  • AI adoption in clinical trials could raise data privacy concerns and regulatory scrutiny.
  • Significant investment in new facilities may face construction delays or cost overruns.

What makes Merck unique

  • Merck's acquisition of Verona Pharma enhances its cardio-pulmonary treatment portfolio.
  • Collaboration with Benchling improves vaccine development efficiency through enhanced bioanalytical workflows.
  • Use of large language models accelerates clinical study report drafting, speeding up drug development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Merck
Jul 10th, 2025
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade - Merck.com

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. Through this acquisition Merck will add Ohtuvayre ® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio. The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the

BioPharma Dive
Jul 9th, 2025
Merck to buy Verona and its lung drug in $10B deal

Merck to buy Verona and its lung drug in $10B deal.

Merck
Jun 25th, 2025
Merck Expands Innovative Internal Generative AI Solutions Helping to Deliver Medicines to Patients Faster

In collaboration with McKinsey & Company and its AI arm, QuantumBlack, Merck technologists and clinical trial experts have developed new solutions leveraging large language models (LLMs) to expedite the creation of first drafts of clinical study reports (CSRs), from two to three weeks to just three to four days.

Merck
Jun 24th, 2025
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention

Today, Merck is developing a series of antiviral options designed to help people manage and help prevent HIV, with the goal of reducing the growing burden of infection worldwide.

Insider Monkey
Jun 18th, 2025
Dividend Growth Remains a Key Priority for Merck

Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks for dependable dividend growth.